Cellectis (CLLS) Cash from Financing Activities (2015 - 2026)
Cellectis' (CLLS) quarterly Cash from Financing Activities came in at -$4.9 million in Q1 2026, down 19.8% year-on-year from -$6.1 million in Q1 2025, and down 18.36% quarter-over-quarter from -$4.1 million in Q4 2025.
Cellectis (CLLS) Cash from Financing Activities (2015 - 2026) Analysis & Trends
Cellectis' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at -$4.9 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 19.8% year-over-year to -$4.9 million in Q1 2026; TTM through Mar 2026 was -$17.6 million, a 124.03% decrease from a year earlier, with the FY2025 full-year figure at -$16.8 million, down 118.81% from the prior year.
- Cash from Financing Activities retreated to -$4.9 million in Q1 2026 per CLLS's latest filing, from -$4.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $78.5 million in Q2 2024 and bottomed at -$4.9 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is $1.7 million (2023), against an average of $8.8 million.
- Across the five-year window, Cash from Financing Activities jumped 976.64% in 2023 and plunged 350.03% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $3.9 million in 2022, then soared by 976.64% to $41.6 million in 2023, then tumbled by 92.97% to $2.9 million in 2024, then sank by 241.54% to -$4.1 million in 2025, then slipped by 18.36% to -$4.9 million in 2026.
- Per Business Quant, the three latest CLLS Cash from Financing Activities figures stand at -$4.9 million (Q1 2026), -$4.1 million (Q4 2025), and -$4.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -4.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.90 Mn |
| Mar 31, 2026 | -4.90 Mn |
| Dec 31, 2025 | -4.14 Mn |
| Dec 31, 2025 | -4.14 Mn |
| Sep 30, 2025 | -4.26 Mn |
| Sep 30, 2025 | -4.26 Mn |
| Jun 30, 2025 | -4.27 Mn |
| Jun 30, 2025 | -4.27 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | 78.51 Mn |
| Jun 30, 2024 | 78.51 Mn |
| Mar 31, 2024 | 11.90 Mn |
| Mar 31, 2024 | 11.90 Mn |
| Dec 31, 2023 | 41.58 Mn |
| Dec 31, 2023 | 41.58 Mn |